| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
MTIC targets DNA in cancer cells. As an alkylating agent, it transfers a methyl group to DNA, primarily at the O⁶ position of guanine. This methylation causes DNA damage, leading to cell cycle arrest and apoptosis. The compound's mechanism of action is central to the therapeutic efficacy of temozolomide and dacarbazine in treating various cancers, particularly melanoma and glioblastoma.
|
|---|---|
| ln Vitro |
In vitro, MTIC is the active metabolite responsible for the anticancer and antitumor activity of temozolomide. It is used in research to study the mechanisms of DNA alkylation and repair, particularly the role of the DNA repair enzyme MGMT (O⁶-methylguanine-DNA methyltransferase). Cells deficient in MGMT are more sensitive to MTIC, making it a valuable tool for studying chemoresistance.
|
| ln Vivo |
In vivo, MTIC is the primary pharmacologically active species following administration of temozolomide. It is responsible for the drug's antineoplastic effects. However, compared to TMZ, MTIC has lower bioavailability in the brain because its permeability through biological barriers and tumor cell membranes is reduced. This property influences the drug's efficacy against brain tumors.
|
| Enzyme Assay |
In vitro enzyme assays for MTIC typically involve studying its alkylating activity on DNA. DNA is incubated with MTIC, and the formation of methylated DNA adducts (e.g., O⁶-methylguanine) is quantified by HPLC or LC-MS. The compound's ability to inhibit DNA synthesis can be measured by monitoring the incorporation of radiolabeled nucleotides.
|
| Cell Assay |
For in vitro cell assays, cancer cell lines (e.g., glioblastoma, melanoma) are cultured and treated with MTIC. Cell viability is assessed by MTT or SRB assays. DNA damage is evaluated by comet assay or by measuring γ-H2AX foci formation. The compound's effects on cell cycle progression and apoptosis are analyzed by flow cytometry.
|
| Animal Protocol |
For in vivo animal studies, MTIC is typically studied as the active metabolite of temozolomide. Animals are administered temozolomide, and MTIC levels are measured in plasma and tissues by LC-MS. In tumor xenograft models, the compound's antitumor efficacy is evaluated by measuring tumor growth inhibition.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
MTIC is a known metabolite of dacarbazine in the human body. MTIC has a molecular formula of C₅H₈N₆O and a molecular weight of 168.16. It is typically a solid and is stable under recommended storage conditions. It is soluble in DMSO and other organic solvents. The compound is a monocarboxylic acid amide and a member of imidazoles. |
| Toxicity/Toxicokinetics |
MTIC is for research use only. As an alkylating agent, it is genotoxic and potentially carcinogenic. It should be handled with extreme caution, using appropriate personal protective equipment and working in a fume hood. Its toxicity profile is consistent with that of other DNA alkylating agents.
|
| References |
|
| Additional Infomation |
MTIC is a monocarboxylic acid amide, a derivative of dacarbazine, in which one methyl group is replaced by a hydrogen atom. It is the active metabolite of dacarbazine and also a product of the spontaneous hydrolysis of temozolomide in vivo. MTIC has alkylating agent and antitumor drug effects. It is a monocarboxylic acid amide, belonging to the imidazole class of compounds and triazine derivatives.
MTIC (CAS# 3413-72-7) is the active metabolite of the anticancer drug temozolomide. It has not been approved as a standalone therapeutic agent. The compound is used in cancer research to study DNA alkylation, chemoresistance, and the mechanisms of action of temozolomide and dacarbazine. It is also known as the temozolomide metabolite MTIC. |
| Molecular Formula |
C5H8N6O
|
|---|---|
| Molecular Weight |
168.16
|
| Exact Mass |
168.076
|
| CAS # |
3413-72-7
|
| Related CAS # |
MTIC-d3;1185242-69-6
|
| PubChem CID |
76953
|
| Appearance |
Brown to orange solid powder
|
| Density |
1.66g/cm3
|
| Boiling Point |
306.7ºC at 760mmHg
|
| Flash Point |
139.3ºC
|
| Index of Refraction |
1.741
|
| LogP |
0.817
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
192
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN=NNC1=C(NC=N1)C(=O)N
|
| InChi Key |
MVBPAIHFZZKRGD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H8N6O/c1-7-11-10-5-3(4(6)12)8-2-9-5/h2H,1H3,(H2,6,12)(H,7,10)(H,8,9)
|
| Chemical Name |
4-(2-methyliminohydrazinyl)-1H-imidazole-5-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (148.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (14.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9467 mL | 29.7336 mL | 59.4672 mL | |
| 5 mM | 1.1893 mL | 5.9467 mL | 11.8934 mL | |
| 10 mM | 0.5947 mL | 2.9734 mL | 5.9467 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
